Original Article

Mild Metabolic Abnormalities, Abdominal Obesity and the Risk of Cardiovascular Diseases in Middle-Aged Japanese Men

Wataru Hirokawa¹, Koshi Nakamura¹, Masaru Sakurai¹, Yuko Morikawa¹, Katsuyuki Miura², Masao Ishizaki³, Katsushi Yoshita⁴, Teruhiko Kido⁵, Yuchi Naruse⁶, and Hideaki Nakagawa¹

¹Department of Epidemiology and Public Health, Kanazawa Medical University, Uchinada, Japan

²Department of Health Science, Shiga University of Medical Science, Otsu, Japan

³Department of Social and Environmental Medicine, Kanazawa Medical University, Uchinada, Japan

⁴Nutritional Epidemiology Program, National Institute of Health and Nutrition, Tokyo, Japan

⁵School of Health Sciences, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan

⁶Department of Human Science and Fundamental Nursing, Toyama University School of Nursing, Toyama, Japan

Aim: We investigated the individual and population impacts of mild abnormalities associated with metabolic syndrome (blood pressure, lipids and glucose) and abdominal obesity, for which lifestyle modification is initially applicable, on cardiovascular disease risk.

Methods: Using a cohort study of 2,685 Japanese men aged 35 to 59 years with an 11-year follow-up period, we calculated the relative risks for cardiovascular diseases due to mild metabolic abnormalities that included at least one of the following three conditions: 1) systolic blood pressure 130–139 mmHg and/or diastolic blood pressure 85–89 mmHg; 2) triglycerides 150–299 mg/dL and/or high-density lipoprotein cholesterol 35–39 mg/dL; and 3) fasting plasma glucose 110–125 mg/dL and/or abdominal obesity. Participants with a mild metabolic abnormality were compared to participants with no metabolic abnormality or abdominal obesity. The population attributable fraction of these abnormalities for cardiovascular diseases was also estimated.

Results: At baseline, 9.8% and 21.8% of the total population had a mild metabolic abnormality with or without abdominal obesity, respectively, while 7.5% had isolated abdominal obesity without any metabolic abnormality. A mild metabolic abnormality with or without abdominal obesity and isolated abdominal obesity increased the risk of cardiovascular disease by 2.68-fold, 1.49-fold, and 2.36-fold, respectively. Approximately 20% of cardiovascular diseases in the total population were attributable to either mild metabolic abnormalities or isolated abdominal obesity.

Conclusion: The importance of lifestyle modification should be acknowledged, especially in cases of mild metabolic abnormality and/or abdominal obesity, which may contribute to approximately 20% of the population burden for cardiovascular diseases.

J Atheroscler Thromb, 2010; 17:934-943.

Key words; Abdominal obesity, Blood pressure, Cardiovascular diseases, Glucose, Lipids

Introduction

Cardiovascular risk factors, such as elevated blood pressure, abnormal lipid profiles and disordered glu-

cose metabolism, have a graded linear relationship with the risk of cardiovascular diseases, including coronary heart disease and stroke¹⁻⁵). On the basis of this evidence, more rigorous intervention is applicable for worse conditions. Thus, individuals with moderate-to-severely abnormal findings are generally required to be under medical control. Individuals with only mildly abnormal findings are usually encouraged to improve these abnormalities, using non-pharmacological therapy, at health checkups and with healthcare advice,

Address for correspondence: Koshi Nakamura, Department of Epidemiology and Public Health, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan
E-mail: knaka@kanazawa-med.ac.jp

Received: November 25, 2009

Accepted for publication: February 12, 2010

even though the individuals may have several mildly abnormal findings.

In 2008, the Japanese national government introduced a nationwide public health strategy to reduce the burden of cardiovascular diseases due to abdominal obesity and associated metabolic disorders, mainly elevated blood pressure, high triglycerides, low high-density lipoprotein (HDL) cholesterol, and disordered glucose metabolism⁶⁻⁸. In this strategy, which is influenced by the Japanese concept and diagnostic criteria of metabolic syndrome⁹, priority is given to obese individuals who have metabolic disorders, with the concept that such individuals should modify their lifestyle in order to decrease the accumulation of abdominal fat, which in turn may lead to the control of blood pressure and lipid and glucose levels. In addition, the severity of metabolic disorders is also considered to determine whether individuals should be treated first using pharmacological or non-pharmacological therapies. Although non-obese individuals with a metabolic abnormality are not prior candidates in this strategy, appropriate healthcare advice should be provided for such non-obese individuals. Non-obese individuals with a mild metabolic abnormality are also in need of non-pharmacological therapy initially, but this therapy is, at least partially, different from what is required for obese individuals with a mild metabolic abnormality. There is therefore a need to examine the risk of developing cardiovascular diseases, taking into account the above situations as they apply to the Japanese population. It is particularly important for public health purposes, such as medical checkups and healthcare advice, to estimate the population burden of cardiovascular diseases due to mild metabolic abnormality with and without abdominal obesity, for which appropriate non-pharmacological therapy should be applied, depending on the presence or absence of abdominal obesity. To the best of our knowledge, little is known about the risk of developing cardiovascular diseases due to mild metabolic abnormalities associated with metabolic syndrome and/or abdominal obesity in the Japanese population, as previous studies have mainly examined the association between metabolic disorders (or morbid conditions pursuant to this syndrome) and the risk of these diseases, without considering the severity of the metabolic disorders and excluding individuals who are taking medication for metabolic disorders¹⁰⁻¹⁸. We used a cohort study in middle-aged Japanese men to investigate the individual and population impacts of mild abnormalities associated with metabolic syndrome and/or abdominal obesity on the risk of cardiovascular diseases.

Participants and Methods

Study Design and Participants

The study population consisted of Japanese men who worked for a metal products factory in Toyama prefecture, Japan. The Industrial Safety and Health Law in Japan requires employers to conduct annual health examinations for all employees. Details of this study population have been reported previously^{15, 19, 20}. A total of 2,952 male employees aged 35 to 59 years, who underwent a health examination in 1996, were enrolled in the study, with subsequent follow-up for 11 years until March 2007. The present cohort study was approved by the Institutional Review Committee of Kanazawa Medical University for Ethical Issues.

Of the 2,952 participants, 267 were excluded due to either a history of previous cardiovascular disease ($n=11$), taking medications for either hypertension, hypercholesterolemia, hypertriglyceridemia and/or diabetes ($n=211$), missing information at the time of the baseline survey ($n=12$), or failure to obtain information in the follow-up survey ($n=33$). The remaining 2,685 participants were included in the analyses.

Baseline Examination

Data collected at study entry included age, medical history, smoking and alcohol drinking habits, leisure-time physical activity, and anthropometric indices, including waist circumference, blood pressure, serum total cholesterol, HDL cholesterol, triglycerides and fasting plasma glucose. Fasting blood samples were obtained by cubital venipuncture and then shipped to one laboratory (BML, Inc., Toyama, Japan) for analysis. Plasma glucose levels were measured enzymatically using an automatic analyzer. Total cholesterol and triglyceride levels were measured by enzyme assay using another automatic analyzer, while HDL cholesterol levels were measured by a direct determination method. A single blood pressure measurement was carried out by trained staff using a mercury sphygmomanometer after the participants had rested for five minutes in the seated position. Waist circumference was measured above the iliac crest and below the lowest rib margin during minimal respiration in the standing position. Medical history, cigarette smoking and alcohol drinking habits, and leisure-time physical activity were evaluated using a self-administered questionnaire.

Definition of the Absence or Presence of Mild or Moderate-to-Severe Metabolic Abnormalities and Abdominal Obesity

Abnormalities in blood pressure, lipids (triglycer-

Table 1. Definition of normal, mildly abnormal and moderate-to-severely abnormal levels of blood pressure, lipids and glucose

	Normal	Abnormal	
		Mildly	Moderate-to-severely
Blood pressure	SBP < 130 mmHg	SBP 130–139 mmHg	SBP ≥ 140 mmHg
	and DBP < 85 mmHg	and/or DBP 85–89 mmHg	and/or DBP ≥ 90 mmHg
Lipids	TG < 150 mg/dL	TG 150–299 mg/dL	TG ≥ 300 mg/dL
	and HDL-C ≥ 40 mg/dL	and/or HDL-C 35–39 mg/dL	and/or HDL-C ≥ 34 mg/dL
Glucose	FPG < 110 mg/dL	FPG 110–125 mg/dL	FPG ≥ 126 mg/dL

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglycerides; HDLC, high-density lipoprotein cholesterol; FPG, fasting plasma glucose.

The present definitions were based on the Japanese metabolic syndrome criteria⁹⁾ and the Japanese *Tokutei Kenshin Tokutei Hoken Shidou* (health checkups and healthcare advice specifically focusing on metabolic syndrome) criteria^{6–8)}; the lower cut-off value of mildly abnormal glucose was defined using the former criteria.

ides and/or HDL cholesterol) and glucose were defined using the criteria of the Japanese Society of Internal Medicine on behalf of the Japanese Committee to Evaluate Diagnostic Standards for Metabolic Syndrome⁹⁾. Each abnormality was then classified further as being either mildly or moderate-to-severely abnormal, using the criteria adopted by the Japanese health checkups and healthcare advice, with particular focus on metabolic syndrome (*Tokutei Kenshin Tokutei Hoken Shidou*)^{6–8)}. Mildly abnormal blood pressure, lipids (triglycerides and/or HDL cholesterol), and glucose were defined as meeting the criteria for which individuals need support to modify their undesirable lifestyle in order to improve metabolic disorders according to the criteria of the *Tokutei Kenshin Tokutei Hoken Shidou* (health checkups and healthcare advice specifically focusing on metabolic syndrome). Moderately-to-severely abnormal blood pressure, lipids and glucose were defined as meeting the criteria for which individuals should be advised to consult a physician. Details of this classification are shown in **Table 1**. The lower cut-off value for mildly abnormal glucose was set as 110 mg/dL, which represents the Japanese metabolic syndrome criteria⁹⁾ and not 100 mg/d, the criteria used in the Japanese *Tokutei Kenshin Tokutei Hoken Shidou* (health checkups and healthcare advice specifically focusing on metabolic syndrome)^{6–8)}.

The study participants were diagnosed as having no, mild, or moderate-to-severe metabolic abnormality after comprehensive evaluation of blood pressure, lipids, and glucose (**Table 2**). Participants who did not have abnormal blood pressure, lipid profile or glucose levels were classified as having “no metabolic abnor-

malty”. Participants who had at least one mild abnormality of either blood pressure, lipids or glucose without moderate-to-severely abnormal blood pressure, lipids or glucose were classified as having a “mild metabolic abnormality”. Participants who had at least one moderate-to-severe abnormality in either blood pressure, lipids or glucose were classified as having a “moderate-to-severe metabolic abnormality”.

Abdominal obesity, defined as a waist circumference ≥ 85 cm, was treated separately from abnormal blood pressure, lipids and glucose, as the criteria for Japanese metabolic syndrome regards it as a mandatory element⁹⁾.

Follow-Up Survey

Vital status and the incidence of cardiovascular diseases were ascertained in March 2007, representing a follow-up period of over 11 years. For participants who stayed at the target factory, questionnaires on medical history at annual health checkups and medical certifications of sickness absence were used to obtain information on the cardiovascular disease history during the follow-up period. For retired participants, questionnaires on cardiovascular disease history were sent annually by mail. For deceased participants, information was obtained from family members. The medical records of every participant who was considered as having a history of cardiovascular disease from this procedure were reviewed to confirm the diagnosis, without knowledge of the variables at baseline. In some deceased cases, death certifications were referenced. If a participant had died or a retired participant did not reply to the questionnaire on cardiovascular disease history, follow-up was stopped at that point.

Table 2. Definition of no, mild, or moderate-to-severe metabolic abnormality after comprehensively evaluating blood pressure, lipids and glucose

No metabolic abnormality	Mild metabolic abnormality	Moderate-to-severe metabolic abnormality
Having all the following conditions: 1) Normal blood pressure (SBP < 130 mmHg and DBP < 85 mmHg) 2) Normal lipids (TG < 150 mg/dL and HDL-C ≥ 40 mg/dL) 3) Normal glucose (FPG < 110 mg/dL)	Having at least one of the following conditions: 1) Mildly abnormal blood pressure (SBP 130–139 mmHg and/or DBP 85–89 mmHg) 2) Mildly abnormal lipids (TG 150–299 mg/dL and/or HDL-C 35–39 mg/dL) 3) Mildly abnormal glucose (FPG 110–125 mg/dL) without any of the following conditions: 1) Moderate-to-severely abnormal blood pressure (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg) 2) Moderate-to-severely abnormal lipids (TG ≥ 300 mg/dL and/or HDL-C ≥ 34 mg/dL) 3) Moderate-to-severely abnormal glucose (FPG ≥ 126 mg/dL)	Having at least one of the following conditions: 1) Moderate-to-severely abnormal blood pressure (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg) 2) Moderate-to-severely abnormal lipids (TG ≥ 300 mg/dL and/or HDL-C ≥ 34 mg/dL) 3) Moderate-to-severely abnormal glucose (FPG ≥ 126 mg/dL)

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; FPG, fasting plasma glucose.

The diagnostic criteria for myocardial infarction were modified from those of the MONITORING trends and determinants of CARDiovascular disease (MONICA) project conducted by the World Health Organization²¹. Myocardial infarction was defined as suffering typical chest pain with findings of abnormal and persistent Q or QS waves on an electrocardiogram and/or changes in cardiac enzyme activity. Sudden cardiac death was defined as death within one hour of onset, a witnessed cardiac arrest or abrupt collapse. Angina pectoris was also included as a coronary heart disease event in individuals who underwent coronary artery angioplasty or bypass surgery. Stroke was defined as suffering a focal neurological disorder with rapid onset, which persisted for at least 24 hours or until death, with supporting evidence from imaging examinations, such as computed tomography or magnetic resonance imaging. The diagnosis of stroke subtype was classified on the basis of the imaging examinations.

The outcome used in the present study was a first-ever incident event of all cardiovascular diseases that included coronary heart disease and stroke. The former included myocardial infarction, sudden cardiac death, and angina pectoris requiring an intervention for the coronary arteries, while the latter included cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and unspecified stroke.

Statistical Analysis

The three metabolic abnormality groups (i.e., no, mild, or moderate-to-severe metabolic abnormality)

defined in the previous section (Table 2) were stratified further according to the presence or absence of abdominal obesity. This yielded the following six groups: 1) no metabolic abnormality without abdominal obesity; 2) mild metabolic abnormality without abdominal obesity; 3) moderate-to-severe metabolic abnormality without abdominal obesity; 4) no metabolic abnormality with abdominal obesity; 5) mild metabolic abnormality with abdominal obesity; and 6) moderate-to-severe metabolic abnormality with abdominal obesity. Hazard ratios, compared to the no metabolic abnormality without abdominal obesity group, were calculated for the five other groups. A Cox proportional hazard model was used to calculate the hazard ratios and their corresponding 95% confidence intervals for the outcomes in each group. This model incorporated the following variables as covariates: age (35–39, 40–44, 45–49, 50–54, 55–59 years), smoking habits (current, former, never smoked), drinking habits (heavy, light, occasional, no drinking), leisure-time physical activity (hard, moderate, light, no activity) and non-HDL cholesterol level (< 170, ≥ 170 mg/dL). Non-HDL cholesterol was calculated as total cholesterol – HDL cholesterol and was used as a covariate instead of low-density lipoprotein cholesterol, the level of which could not be calculated for participants with extremely high triglyceride levels²².

The population attributable fraction, which represents the contribution of mild and moderate-to-severe metabolic abnormalities to cardiovascular disease in the study population, was then estimated as

Table 3. Baseline risk characteristics of the 2,685 male study participants in a workplace, Toyama, Japan (1996). Data are presented for the total study population and also grouped according to metabolic abnormality and abdominal obesity status.

	Overall	Without abdominal obesity			With abdominal obesity			<i>p</i> values [†]
		No metabolic abnormality	Mild metabolic abnormality	Moder-to-sev metabolic abnormality	No metabolic abnormality	Mild metabolic abnormality	Moder-to-sev metabolic abnormality	
Participants	2,685	1,015	584	342	202	264	242	
Age (yrs)	45.2 (± 6.5)	44.3 (± 6.2)	45.3 (± 6.3)	47.0 (± 6.8)	44.9 (± 6.2)	45.0 (± 6.2)	47.0 (± 6.9)	<0.01
Height (cm)	167.8 (± 6.0)	167.4 (± 6.0)	167.2 (± 6.1)	167.0 (± 6.1)	169.1 (± 5.8)	169.2 (± 6.0)	168.8 (± 6.0)	<0.01
Weight (kg)	65.4 (± 8.8)	61.4 (± 6.7)	62.9 (± 6.6)	62.7 (± 7.2)	73.8 (± 6.5)	75.0 (± 7.0)	75.4 (± 7.0)	<0.01
Body mass index (kg/m ²)	23.2 (± 2.7)	21.8 (± 2.0)	22.5 (± 2.1)	22.4 (± 2.1)	25.8 (± 2.0)	26.1 (± 2.2)	26.4 (± 2.1)	<0.01
Waist circumference (cm)	79.8 (± 7.6)	75.4 (± 5.4)	77.6 (± 4.9)	77.7 (± 4.9)	88.7 (± 3.7)	89.3 (± 4.0)	89.8 (± 4.3)	<0.01
Cigarette smoking (%)								0.34
Never	29.1%	29.8%	26.7%	31.9%	29.2%	29.5%	27.3%	
Former	11.3%	10.3%	10.8%	10.5%	15.3%	11.0%	14.9%	
Current	59.6%	59.9%	62.5%	57.6%	55.4%	59.5%	57.9%	
Alcohol drinking (%)								<0.01
No	22.7%	24.5%	20.5%	19.3%	18.3%	23.9%	27.3%	
Occasional	30.9%	31.0%	32.2%	28.9%	32.7%	29.2%	30.2%	
Light	27.6%	28.4%	26.0%	28.9%	29.7%	31.8%	19.4%	
Heavy	18.8%	16.1%	21.2%	22.8%	19.3%	15.2%	23.1%	
Leisure-time physical activity (%)								0.10
No	66.6%	66.7%	67.5%	61.7%	66.8%	68.2%	68.6%	
Light	19.4%	17.1%	19.9%	22.8%	21.3%	18.2%	23.6%	
Moderate	9.9%	11.4%	8.6%	10.8%	8.4%	10.6%	5.4%	
Hard	4.1%	4.8%	4.1%	4.7%	3.5%	3.0%	2.5%	
Systolic blood pressure (mmHg)	121.3 (± 13.3)	113.4 (± 8.6)	123.8 (± 10.7)	135.3 (± 14.4)	115.3 (± 7.8)	123.6 (± 10.0)	132.6 (± 14.1)	<0.01
Diastolic blood pressure (mmHg)	76.3 (± 10.0)	70.9 (± 7.2)	77.1 (± 8.2)	86.1 (± 10.5)	72.9 (± 7.0)	78.3 (± 7.3)	84.4 (± 10.8)	<0.01
Serum triglycerides (mg/dL)*	99 (70–146)	79 (61–102)	126 (81–173)	115 (72–177)	94 (72–116)	153 (100–190)	164 (110–260)	<0.01
Serum HDL cholesterol (mg/dL)	55.2 (± 15.0)	59.9 (± 14.1)	54.5 (± 14.7)	54.7 (± 18.2)	53.0 (± 9.7)	48.5 (± 11.8)	45.8 (± 13.9)	<0.01
Serum non-HDL cholesterol (mg/dL)	148.5 (± 34.0)	139.1 (± 31.0)	149.6 (± 34.9)	150.3 (± 36.2)	150.6 (± 28.4)	163.3 (± 32.2)	166.9 (± 32.6)	<0.01
Fasting plasma glucose (mg/dL)*	90 (85–97)	88 (83–93)	91 (85–97)	94 (87–105)	89 (85–95)	92 (86–98)	97 (89–109)	<0.01

Abbreviations: HDL cholesterol, high-density lipoprotein cholesterol; Moder-to-sev, Moderate-to-severe.

Values are expressed as the mean (± standard deviation), median (interquartile range) or the % of participants in that category; * median is presented due to the skewed distributions.

[†] One-way analysis of variance, Kruskal Wallis test or chi-square tests were used to compare each risk characteristic among the six groups.

proportion × (hazard ratio − 1)/hazard ratio²³⁾, using the proportion of incident cases in the metabolic abnormality group and the multivariate-adjusted hazard ratio derived from this analysis.

Statistical analyses were performed using the Statistical Package for the Social Sciences Version 12.0J for Windows (SPSS Japan Inc., Tokyo, Japan). All probability values were two-tailed and the significance level was set at $p < 0.05$.

Results

Characteristics of the Study Population

The baseline characteristics of the 2,685 study participants in total and grouped according to the severity of metabolic abnormality and abdominal obesity status are summarized in **Table 3**. The mean age of the study population was 45.2 years. Of the total participants, 39.1% had neither metabolic abnormal-

Table 4. Hazard ratios for the incidence of cardiovascular disease due to mildly or moderate-to-severely abnormal levels of each metabolic disorder and abdominal obesity, in 2,685 male participants over 11 years of follow-up (1996–2007)

		Cardiovascular diseases	
		Events	Multivariate-adjusted HR (95% CI)*
Blood pressure			
Normal	1,768	29	1.00 reference
Mildly abnormal	530	13	1.37 (0.70–2.65)
Moderate-to-severely abnormal	387	16	1.99 (1.04–3.79)
Lipids (triglycerides/high-density lipoprotein cholesterol)			
Normal	1,910	34	1.00 reference
Mildly abnormal	591	16	1.11 (0.60–2.07)
Moderate-to-severely abnormal	184	8	1.27 (0.55–2.93)
Glucose			
Normal	2,483	48	1.00 reference
Mildly abnormal	123	5	1.39 (0.54–3.57)
Moderate-to-severely abnormal	79	5	1.70 (0.65–4.45)
Abdominal obesity status			
Non-obese	1,977	32	1.00 reference
Obese	708	26	1.87 (1.07–3.26)

Abbreviations: HR, hazard ratio; CI, confidence interval.

Hazard ratios, with normal acting as the reference, were calculated using a Cox proportional hazards regression model adjusted for age, smoking habits, drinking habits, leisure-time physical activity, serum non-high-density lipoprotein cholesterol, the three residual factors (blood pressure, lipids, and glucose) and abdominal obesity status.

ity nor abdominal obesity, 21.8% had a mild metabolic abnormality without abdominal obesity, 12.7% had a moderate-to-severe metabolic abnormality without abdominal obesity, 7.5% had isolated abdominal obesity without any metabolic abnormality, 9.8% had a mild metabolic abnormality with abdominal obesity and 9.0% had a moderate-to-severe metabolic abnormality with abdominal obesity. The mean age increased with worsening metabolic abnormalities for participants with and without abdominal obesity. With a few exceptions, mean blood pressure, triglyceride and fasting glucose levels increased with worsening metabolic abnormalities, whereas mean HDL cholesterol decreased with worsening metabolic status. Mean non-HDL cholesterol also increased with worsening metabolic abnormalities.

Individual Risk of Cardiovascular Diseases Due to Each Metabolic Disorder and Abdominal Obesity

The study involved 26,882 person-years of follow-up in the 2,685 study participants. The mean overall follow-up period was 10.0 years. During follow-up, 58 first-ever incident events of cardiovascular diseases were recorded, including 20 myocardial infar-

tions, 4 sudden cardiac deaths, 5 cases of angina pectoris with coronary intervention, 17 cerebral infarctions, 8 cerebral hemorrhages, and 4 subarachnoid hemorrhages. The crude incidence rate of cardiovascular diseases in the study population was 2.16/1000 person-years.

Table 4 shows that the increased severity of elevations in blood pressure, dyslipidemia or disordered glucose metabolism was likely to independently increase the risk of cardiovascular disease. Abdominal obesity was also an independent risk factor for cardiovascular diseases.

Individual Risk of Cardiovascular Diseases Due to Mild or Moderate-to-Severe Metabolic Abnormalities and/or Abdominal Obesity

Table 5 shows the hazard ratios for the incidence of cardiovascular disease due to mild or moderate-to-severe metabolic abnormalities and/or abdominal obesity. Compared to the absence of any metabolic abnormality and abdominal obesity, a moderate-to-severe metabolic abnormality without abdominal obesity, a mild metabolic abnormality with abdominal obesity and a moderate-to-severe metabolic abnormality with

Table 5. Hazard ratios for the incidence of cardiovascular disease due to mild or moderate-to-severe metabolic abnormalities and/or abdominal obesity, in 2,685 male participants over 11 years of follow-up (1996–2007)

	No metabolic abnormality	Mild metabolic abnormality	Moderate-to-severe metabolic abnormality
Without abdominal obesity			
Participants	1,051	584	342
Total person-years of follow-up	10,739	5,821	3,399
Cardiovascular events	11	10	11
Crude rate per 1000 person-years	1.02	1.72	3.24
Age-adjusted HR (95% CI)*	1.00 reference	1.54 (0.65–3.63)	2.51 (1.08–5.82)
Multivariate-adjusted HR (95% CI)**	1.00 reference	1.49 (0.63–3.52)	2.52 (1.08–5.87)
With abdominal obesity			
Participants	202	264	242
Total person-years of follow-up	1,982	2,611	2,329
Cardiovascular events	5	8	13
Crude rate per 1000 person-years	2.52	3.06	5.58
Age-adjusted HR (95% CI)*	2.34 (0.81–6.74)	2.81 (1.13–7.00)	4.36 (1.94–9.82)
Multivariate-adjusted HR (95% CI)**	2.36 (0.81–6.82)	2.68 (1.07–6.73)	4.12 (1.80–9.43)

Abbreviations: HR, hazard ratio; CI, confidence interval.

Hazard ratios were calculated by a Cox proportional hazards regression model, with no metabolic abnormality without abdominal obesity acting as the reference; *adjusted for age; **adjusted for age, smoking habits, drinking habits, leisure-time physical activity and serum non-high-density lipoprotein cholesterol.

abdominal obesity increased the risk of cardiovascular disease by 2.52-fold, 2.68-fold, and 4.12-fold, respectively. All three of these hazard ratios were statistically significant. Mild metabolic abnormality without abdominal obesity and isolated abdominal obesity without any metabolic abnormality also tended to increase the risk of cardiovascular disease by 1.49-fold and 2.36-fold, respectively.

Population Risk of Cardiovascular Diseases Due to Mild or Moderate-to-Severe Metabolic Abnormalities and/or Abdominal Obesity

Fig. 1 shows the estimations of population attributable fractions for cardiovascular disease. These calculations showed that 19.3% of cardiovascular diseases that occurred in the study population were attributable to either a mild metabolic abnormality or abdominal obesity alone without any metabolic abnormality, 5.7% to a mild metabolic abnormality without abdominal obesity, 5.0% to isolated abdominal obesity, and 8.6% to a mild metabolic abnormality with abdominal obesity. Furthermore, 28.4% of cardiovascular diseases were attributable to a moderate-to-severe metabolic abnormality.

Discussion

This cohort study in middle-aged Japanese men

demonstrated that the risk of cardiovascular disease was likely to be higher in participants who had a mild metabolic abnormality either with or without abdominal obesity and in participants who had isolated abdominal obesity without any metabolic abnormality for whom non-pharmacological therapy was required initially, compared to participants who had neither a metabolic abnormality nor abdominal obesity. Mild metabolic abnormality or isolated abdominal obesity contributed up to 20% of the cardiovascular diseases that occurred in the study population. The unique feature of this report is that the risk of cardiovascular disease due to the components of metabolic syndrome was evaluated from the viewpoint of intervention as a priority in health checkups and healthcare advice.

The mild metabolic abnormality based on our definitions is usually considered to require non-pharmacological therapy initially to improve the abnormality, regardless of the presence or absence of abdominal obesity. In contrast, moderate-to-severe metabolic abnormality based on our definitions is usually considered to require consultation with a physician⁽⁶⁻⁸⁾. Our results are reasonable according to this principle of health checkups and healthcare advice, when we viewed our results separately in obese and non-obese participants. The risk of cardiovascular disease tended to be the first and second highest in participants with a moderate-to-severe metabolic abnormality and in

Fig. 1. Population attributable fraction for the incidence of cardiovascular disease due to mild or moderate-to-severe metabolic abnormalities and/or abdominal obesity, in the study population over 11 years of follow-up (1996-2007).

participants with a mild metabolic abnormality, respectively, regardless of the abdominal obesity status, despite the corresponding risk originally being higher in participants with abdominal obesity than in those without. Surprisingly, our results indicate that some obese individuals with a mild metabolic abnormality have a cardiovascular risk that is as high as that in non-obese individuals with a moderate-to-severe metabolic abnormality. This suggests that it may be better to advise some obese individuals with a mild metabolic abnormality to consult a physician prior to recommending non-pharmacological therapy, due to their possible high risk of cardiovascular disease. Obese participants with two or more mild metabolic disorders, who met the Japanese metabolic syndrome criteria (i.e., presence of abdominal obesity accompanied by two or more metabolic disorders)⁹⁾, may have a higher cardiovascular risk than obese participants with only a single metabolic disorder. This concern arises from the findings of a previous study in a Western population carried out by Vasan and colleagues²⁴⁾. They observed that coronary heart disease event rates rose with increasing number of borderline abnormalities in blood pressure (systolic 120-139 mmHg or diastolic 80-89 mmHg), serum low-density lipoprotein cholesterol (100-159 mg/dL), high-density lipoprotein cholesterol (40-59 mg/dL), glucose (fasting 110-125 mg/dL or 2-hour post-prandial 140-199 mg/dL) and smoking habits (former smoking), although this previous study did not investigate abdominal

obesity or serum triglycerides, which are components of the metabolic syndrome, but did record serum low-density lipoprotein cholesterol levels and smoking habits²⁴⁾. In fact, the Japanese *Tokutei Kenshin Tokutei Hoken Shidou* (health checkups and healthcare advice specifically focusing on metabolic syndrome) criteria⁶⁻⁸⁾ places importance on both the number and severity of metabolic abnormalities in health checkups and healthcare advice. Unfortunately, our study did not include a sufficiently large number of participants or events to conduct additional analyses using the number of mild metabolic abnormalities to further classify the participants. Further studies on a greater number of participants and cases are therefore warranted to clarify whether there is a further increase in cardiovascular disease risk in individuals with a cluster of mild metabolic disorders, compared to individuals with only a single metabolic disorder.

When non-obese and obese individuals were combined in our analyses, the burden of cardiovascular disease due to mild metabolic abnormalities and isolated abdominal obesity was equivalent to approximately two-thirds of the corresponding burden due to moderate-to-severe metabolic abnormalities. Approximately 15% of cardiovascular diseases in our study population were attributable to either abdominal obesity in association with a mild metabolic abnormality or isolated abdominal obesity. Ideally, rigorous lifestyle modification that decreases the accumulation of abdominal fat without the administration of medica-

tion is initially applicable. In other words, a value of 15% represents the ideal expected reduction in the burden of cardiovascular disease resulting from rigorous lifestyle modification to decrease abdominal fat accumulation without the need to take medication. On the other hand, other lifestyle modifications, such as reducing dietary sodium intake, are also of importance, especially in non-obese individuals with mild metabolic abnormalities, a group that contributed to approximately 5% of the cardiovascular diseases observed in our study population. This suggests that non-obese individuals with a mild metabolic abnormality should not be overlooked from the viewpoint of public health for the prevention of cardiovascular diseases in the Japanese population, who are relatively lean. The burden of cardiovascular disease due to combined mild and moderate-to-severe metabolic abnormalities was greater in obese participants than in non-obese participants: 30.6% (=5.0% + 8.6% + 17.0%) vs. 17.1% (=5.7% + 11.4%). This pattern contradicts the finding in a previous Japanese study, which showed a greater population attributable fraction for ischemic cardiovascular disease among non-obese men with metabolic disorders (33%) than obese men with metabolic disorders and individuals with obesity alone (22%)¹⁶. This difference may be partially due to the different characteristics between these two study populations, suggesting that our observed burden of cardiovascular disease due to mild and moderate-to-severe metabolic abnormalities without abdominal obesity is underestimated, whereas the corresponding burden due to mild and moderate-to-severe metabolic abnormalities with abdominal obesity is overestimated.

The present study had several limitations. First, as our study participants consisted solely of male workers in one factory, it is necessary to take care when generalizing our results. Furthermore, participants who had already started to take medication for metabolic disorders prior to study entry were excluded. Second, the metabolic abnormalities in this report included high blood pressure, high triglycerides, low HDL cholesterol, and high glucose, which are components of metabolic syndrome, but did not include high total cholesterol, which is another determinant of cardiovascular disease risk². Dyslipidemia was evaluated using a combination of triglyceride and HDL cholesterol levels based on the Japanese metabolic syndrome criteria⁹. In addition, mildly abnormal glucose control was defined as a fasting glucose level between 110 and 125 mg/dL; however, broadly similar hazard ratios were observed for cardiovascular disease due to mild and moderate-to-severe metabolic abnormalities and/or abdominal obesity, when the lower cut-off

value was set as 100 mg/d, based on the Japanese *Tokutei Kenshin Tokutei Hoken Shidou* (health check-ups and healthcare advice specifically focusing on metabolic syndrome) criteria⁶⁻⁸ (data not shown). Third, we measured waist circumference, using the landmark above the iliac crest and below the lowest rib margin, which is different from the protocol in Japanese metabolic syndrome criteria, which uses the level of the umbilicus for the measurements⁹; however, one study suggested that the association between waist circumference and cardiovascular diseases is unlikely to depend on the measurement protocol²⁵. Fourth, abdominal obesity was treated separately from blood pressure, lipids, and glucose, not only because it is an essential factor in Japanese metabolic syndrome criteria⁹, but also because of a lack of evidence of mild and moderate-to-severe increases in waist circumference. Fifth, the follow-up survey protocol differed between participants who stayed at the target factory and retired participants. Although information on cardiovascular disease could be easily and completely obtained for participants staying at the factory, there were difficulties and failures in obtaining the corresponding information from retired participants. While this difference in data collection may have resulted in bias, the follow-up rate of the cohort was very high (99%) and therefore we consider that it is acceptable to disregard this possibility. Finally, we used a composite outcome in which coronary heart disease and stroke events were combined due to the relatively small number of events. In addition, coronary heart disease included cases of angina pectoris that required intervention for the coronary arteries.

In conclusion, obese and non-obese individuals with mildly abnormal blood pressure, lipids and/or glucose, and obese individuals without any metabolic disorders may have, on average, an approximately 2-fold increased risk of cardiovascular disease, compared to individuals with neither metabolic disorders nor abdominal obesity. The importance of lifestyle modification should be acknowledged, especially in cases of a mild metabolic abnormality and/or abdominal obesity, which may contribute to approximately 20% of the population burden of cardiovascular diseases.

Acknowledgments and Notice of Grant Support

The present study was supported by the Japan Arteriosclerosis Prevention Fund and by research grants from the Ministry of Health, Labour and Welfare (Comprehensive Research on Cardiovascular and Life-Style Related Disease: H17-kenko-007; H18-sei-

shuu-012; H20-seishuu-013, 021).

References

- Asia Pacific Cohort Studies Collaboration: Blood pressure and cardiovascular disease in the Asia Pacific region. *J Hypertens*, 2003; 21: 707-716
- Asia Pacific Cohort Studies Collaboration: Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. *Int J Epidemiol*, 2003; 32: 563-572
- Asia Pacific Cohort Studies Collaboration: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. *Circulation*, 2004; 110: 2678-2686
- Woodward M, Barzi F, Feigin V, Gu D, Huxley R, Nakamura K, Patel A, Ho S, Jamrozik K; Asia Pacific Cohort Studies Collaboration: Associations between high-density lipoprotein cholesterol and both stroke and coronary heart disease in the Asia Pacific region. *Eur Heart J*, 2007; 28: 2653-2660
- Asia Pacific Cohort Studies Collaboration: Blood glucose and risk of cardiovascular disease in the Asia Pacific region. *Diabetes Care*, 2004; 27: 2836-2842
- Ministry of Health, Labour and Welfare of Japan: The basic guideline for health checkups and healthcare advice with a particular focus on the metabolic syndrome (final edition). Ministry of Health, Labour and Welfare of Japan, Tokyo, 2007 (in Japanese)
- Kohro T, Furui Y, Mitsutake N, Fujii R, Morita H, Oku S, Ohe K, Nagai R: The Japanese national health screening and intervention program aimed at preventing worsening of the metabolic syndrome. *Int Heart J*, 2008; 49: 193-203
- Yamamoto H: Health checkups and healthcare advice with a particular focus on the metabolic syndrome in the health care system reform. *J Natl Inst Public Health*, 2008; 57: 3-8 (in Japanese)
- Committee to Evaluate Diagnostic Standards for Metabolic Syndrome: Definition and the diagnostic standard for metabolic syndrome. *J Jpn Soc Int Med*, 2005; 94: 794-809 (in Japanese)
- Ninomiya T, Kubo M, Doi Y, Yonemoto K, Tanizaki Y, Rahman M, Arima H, Tsuruya K, Iida M, Kiyohara Y: Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama study. *Stroke*, 2007; 38: 2063-2069
- Iso H, Sato S, Kitamura A, Imano H, Kiyama M, Yamagishi K, Cui R, Tanigawa T, Shimamoto T: Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. *Stroke*, 2007; 38: 1744-1751 (errata: *Stroke*, 2007; 38: e37)
- Kadota A, Hozawa A, Okamura T, Kadowak T, Nakamura K, Murakami Y, Hayakawa T, Kita Y, Okayama A, Nakamura Y, Kashiwagi A, Ueshima H; NIPPON DATA Research Group: Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990-2000. *Diabetes Care*, 2007; 30: 1533-1538
- Kokubo Y, Okamura T, Yoshimasa Y, Miyamoto Y, Kawanishi K, Kotani Y, Okayama A, Tomoike H: Impact of metabolic syndrome components on the incidence of cardiovascular disease in a general urban Japanese population: the suita study. *Hypertens Res*, 2008; 31: 2027-2035
- Chei CL, Yamagishi K, Tanigawa T, Kitamura A, Imano H, Kiyama M, Sato S, Iso H: Metabolic Syndrome and the Risk of Ischemic Heart Disease and Stroke among Middle-Aged Japanese. *Hypertens Res*, 2008; 31: 1887-1894
- Sakurai M, Miura K, Nakamura K, Ishizaki M, Morikawa Y, Kido T, Naruse Y, Nakagawa H: Relationship between abdominal obesity, accumulation of metabolic abnormalities and risk of cardiovascular disease: An 11-year follow-up of middle-aged Japanese men. *Japanese Journal of Cardiovascular Disease Prevention*, 2009; 44: 1-9 (in Japanese)
- Noda H, Iso H, Saito I, Konishi M, Inoue M, Tsugane S: The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: the Japan public health center-based study. *Hypertens Res*, 2009; 32: 289-298
- Saito I, Iso H, Kokubo Y, Inoue M, Tsugane S: Metabolic syndrome and all-cause and cardiovascular disease mortality. *Circ J*, 2009; 73: 878-884
- Niwa Y, Ishikawa S, Gotoh T, Kayaba K, Nakamura Y, Kajii E: Association between stroke and metabolic syndrome in a Japanese population: Jichi Medical School (JMS) Cohort Study. *J Epidemiol*, 2010; 20: 62-69
- Sakurai M, Miura K, Takamura T, Ota T, Ishizaki M, Morikawa Y, Kido T, Naruse Y, Nakagawa H: Gender differences in the association between anthropometric indices of obesity and blood pressure in Japanese. *Hypertens Res*, 2006; 29: 75-80
- Ishizaki M, Nakagawa H, Morikawa Y, Honda R, Yamada Y, Kawakami N; Japan Work Stress and Health Cohort Study Group: Influence of job strain on changes in body mass index and waist circumference--6-year longitudinal study. *Scand J Work Environ Health*, 2008; 34: 288-296
- Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A: Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. *Circulation*, 1994; 90: 583-612
- Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*, 1972; 18: 499-502
- Rockhill B, Newman B, Weinberg C: Use and misuse of population attributable fractions. *Am J Public Health*, 1998; 88: 15-19 (errata: *Am J Public Health*, 2008; 98: 2119)
- Vasan RS, Sullivan LM, Wilson PW, Sempos CT, Sundström J, Kannel WB, Levy D, D'Agostino RB: Relative importance of borderline and elevated levels of coronary heart disease risk factors. *Ann Intern Med*, 2005; 142: 393-402 (errata: *Ann Intern Med*, 2005; 142: 681)
- Ross R, Berentzen T, Bradshaw AJ, Janssen I, Kahn HS, Katzmarzyk PT, Kuk JL, Seidell JC, Snijder MB, Sørensen TI, Després JP: Does the relationship between waist circumference, morbidity and mortality depend on measurement protocol for waist circumference? *Obes Rev*, 2008; 9: 312-325